Cbdmd Stock Earnings Reports

cbdMD reported stabilization and sequential improvement in Q1 fiscal 2026 with revenue of just over $5.0 million, a 12% increase sequentially and marking the third consecutive quarter of revenue growth. Direct-to-consumer remains the largest channel (≈72%), with wholesale at 28% and showing sequential and year-over-year improvement. Gross margin was 60% (down from 66% a year prior) due to higher warehouse expense and a mix shift toward wholesale. Net loss attributable to common shareholders was about $325,000 (≈$0.04 per share), improved materially on a per-share basis driven by the Series A conversion; adjusted (non-GAAP) EBITDA loss was minimal at $36,000. Cash was roughly $3.3–3.4 million and working capital about $5.4 million at quarter end, supported by a ~$2.25 million Series C preferred financing and a $20 million equity line of credit (ELOC) for opportunistic capitalization. Management completed the strategic acquisition of Bluebird Botanicals' assets in mid-January to broaden the portfolio, access new customers, add IP (including full-spectrum “grass” status), and pursue cost/revenue synergies; integration is a near-term priority. Management emphasized continued cost discipline, focus on high-velocity SKUs and margin protection, active engagement on regulatory developments (including support for the HEMP Act), and participation in forthcoming federal CBD programs. Near-term priorities are driving sequential revenue, integrating Bluebird, extracting synergies, and maintaining balance sheet flexibility to support sustainable, improving operating results.